Real-world outcomes of first-line pembrolizumab monotherapy among dMMR/MSI-H advanced or recurrent endometrial cancer patients in the United States. // Gynecologic Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0090825826021013?dgcid=rss_sd_all
Real-world outcomes of first-line pembrolizumab monotherapy among dMMR/MSI-H advanced or recurrent endometrial cancer patients in the United States. Gynecologic Oncology. https://www.sciencedirect.com/science/article/pii/S0090825826021013?dgcid=rss_sd_all
“Real-world outcomes of first-line pembrolizumab monotherapy among dMMR/MSI-H advanced or recurrent endometrial cancer patients in the United States.” Gynecologic Oncology.
@article{article47519,
title = {Real-world outcomes of first-line pembrolizumab monotherapy among dMMR/MSI-H advanced or recurrent endometrial cancer patients in the United States},
journal = {Gynecologic Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0090825826021013?dgcid=rss_sd_all}
}